IN2012DN00250A - - Google Patents

Info

Publication number
IN2012DN00250A
IN2012DN00250A IN250DEN2012A IN2012DN00250A IN 2012DN00250 A IN2012DN00250 A IN 2012DN00250A IN 250DEN2012 A IN250DEN2012 A IN 250DEN2012A IN 2012DN00250 A IN2012DN00250 A IN 2012DN00250A
Authority
IN
India
Prior art keywords
complexes
purified
protein complexes
provides
peptide
Prior art date
Application number
Other languages
English (en)
Inventor
Camilo Colaco
Colin Richard Bignell
Original Assignee
Immunobiology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Ltd filed Critical Immunobiology Ltd
Publication of IN2012DN00250A publication Critical patent/IN2012DN00250A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/605MHC molecules or ligands thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14041Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN250DEN2012 2009-06-19 2010-06-21 IN2012DN00250A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0910591.7A GB0910591D0 (en) 2009-06-19 2009-06-19 Method for the purification of protein complexes
PCT/GB2010/051023 WO2010146401A1 (en) 2009-06-19 2010-06-21 Method for the purification of protein complexes

Publications (1)

Publication Number Publication Date
IN2012DN00250A true IN2012DN00250A (https=) 2015-05-01

Family

ID=40941082

Family Applications (1)

Application Number Title Priority Date Filing Date
IN250DEN2012 IN2012DN00250A (https=) 2009-06-19 2010-06-21

Country Status (9)

Country Link
US (1) US10040820B2 (https=)
EP (1) EP2442825B1 (https=)
JP (1) JP5778666B2 (https=)
CN (1) CN102458460B (https=)
AU (1) AU2010261505B2 (https=)
GB (1) GB0910591D0 (https=)
IN (1) IN2012DN00250A (https=)
WO (1) WO2010146401A1 (https=)
ZA (1) ZA201200420B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627425A4 (en) * 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
GB201104897D0 (en) 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same
EP2734231A1 (en) * 2011-07-21 2014-05-28 Biotech Tools S.A. Dosage of dnak
US11708553B2 (en) 2017-06-07 2023-07-25 University Of Maryland, Baltimore County Factory-on-a-chip for production of biologically derived medicines/biopharmaceuticals/biologics/biotherapeutics
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
JPH11513369A (ja) * 1995-09-13 1999-11-16 フォーダム ユニバーシティー 熱ショックタンパク質を用いる治療及び予防方法
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
GB9818133D0 (en) 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
GB9919733D0 (en) 1999-08-19 1999-10-20 Colaco Camilo Vaccines against intracellular pathogens
GB9919734D0 (en) 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
GB0021757D0 (en) 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
WO2002028407A1 (en) * 2000-09-29 2002-04-11 University Of Connecticut Health Center Methods of recovering heat shock proteins and complexes thereof
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7132109B1 (en) * 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US6875849B2 (en) * 2001-05-01 2005-04-05 Arizona Board Of Regents Of Behalf Of The University Of Arizona Methods of recovering chaperone proteins and complexes thereof
JP2005533015A (ja) 2002-05-02 2005-11-04 ユニバーシティー オブ コネティカット ヘルス センター 抗体療法の有効性を増強するための熱ショックタンパク質の使用
DE60335549D1 (de) * 2003-11-12 2011-02-10 Alfa Biogene Internat B V Gewinnung von Hitzeschockproteinen
GB0816242D0 (en) * 2008-09-05 2008-10-15 Immunobiology Ltd Method of purifying protien complexes

Also Published As

Publication number Publication date
CN102458460A (zh) 2012-05-16
WO2010146401A1 (en) 2010-12-23
AU2010261505B2 (en) 2015-02-05
ZA201200420B (en) 2018-11-28
JP5778666B2 (ja) 2015-09-16
JP2012530123A (ja) 2012-11-29
GB0910591D0 (en) 2009-07-29
EP2442825B1 (en) 2017-11-08
CN102458460B (zh) 2018-01-30
US10040820B2 (en) 2018-08-07
EP2442825A1 (en) 2012-04-25
US20120135029A1 (en) 2012-05-31
AU2010261505A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
IN2015KN00452A (https=)
MX2024014468A (es) Anticuerpos anti-cd63, conjugados y usos de estos
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
WO2009015842A3 (en) Novel immunogenic epitopes for immunotherapy
MX2012011405A (es) Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas.
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY173004A (en) Mycobacterial antigen vaccine
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
EA201071297A1 (ru) Новые и действенные пептиды мнс ii класса, полученные из сурвивина
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
MX2014004359A (es) Proteina naglu humana recombinante y usos de la misma.
MA32819B1 (fr) Vaccin combine notamment contre la coqueluche acellulaire
MX2019003615A (es) Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas.
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
IN2012DN00250A (https=)
EA201290675A1 (ru) Вакцинные векторы и способы усиления иммунных ответов
EA201500783A1 (ru) Способы получения дикетопиперазинов и соединений, содержащих дикетопиперазины
EA201390676A1 (ru) Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування